Fundamental Analysis of IOVANCE BIOTHERAPEUTICS INC(NASDAQ:IOVA) stock

Fundamental Rating

Taking everything into account, IOVA scores 3 out of 10 in our fundamental rating. IOVA was compared to 588 industry peers in the Biotechnology industry. While IOVA seems to be doing ok healthwise, there are quite some concerns on its profitability. IOVA is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

IOVA had negative earnings in the past year.

IOVA had a negative operating cash flow in the past year.

IOVA had negative earnings in each of the past 5 years.

In the past 5 years IOVA always reported negative operating cash flow.

1.2 Ratios

IOVA has a Return On Assets (-56.90%) which is in line with its industry peers.

IOVA has a Return On Equity (-75.95%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-56.9%
ROE	-75.95%
ROIC	N/A

ROA(3y)-53.52%

ROA(5y)-50.33%

ROE(3y)-70.08%

ROE(5y)-63.17%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IOVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.

IOVA has more shares outstanding than it did 1 year ago.

The number of shares outstanding for IOVA has been increased compared to 5 years ago.

IOVA has a better debt/assets ratio than last year.

2.2 Solvency

IOVA has an Altman-Z score of 5.77. This indicates that IOVA is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of IOVA (5.77) is better than 80.72% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that IOVA is not too dependend on debt financing.

The Debt to Equity ratio of IOVA (0.00) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	5.77

ROIC/WACCN/A

WACC9.27%

2.3 Liquidity

IOVA has a Current Ratio of 2.79. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of IOVA (2.79) is worse than 69.11% of its industry peers.

IOVA has a Quick Ratio of 2.70. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.

IOVA has a Quick ratio of 2.70. This is in the lower half of the industry: IOVA underperforms 68.09% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.79
Quick Ratio	2.7

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.19% over the past year.

EPS 1Y (TTM)24.19%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q29.69%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

IOVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.41% yearly.

IOVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 205.03% yearly.

EPS Next Y30.15%

EPS Next 2Y26.97%

EPS Next 3Y25.99%

EPS Next 5Y28.41%

Revenue Next Year3750.86%

Revenue Next 2Y896.74%

Revenue Next 3Y437.1%

Revenue Next 5Y205.03%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IOVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year IOVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as IOVA's earnings are expected to grow with 25.99% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.97%

EPS Next 3Y25.99%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IOVA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (5/3/2024, 8:36:57 AM)

13.53

+0.65 (+5.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.78B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-56.9%
ROE	-75.95%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.79
Quick Ratio	2.7
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)24.19%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y30.15%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

IOVANCE BIOTHERAPEUTICS INC (IOVA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens